Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

ReNeuron hopes share consolidation will improve the marketability and liquidity of the stock

The stem cell specialist said it wants to reduce its equity base by a factor of 100
researcher inserting stem cells into a test tube
The company is a stem cell specialist

ReNeuron Group Plc (LON:RENE) plans a share consolidation, which it hopes will improve the marketability and liquidity of the stock along with trading activity.

The stem cell specialist said it wants to reduce its equity base by a factor of 100, which, based on Thursday’s close of 1.825p, would push the price to 182.5p.

WATCH: 'Lots to look forward to' as ReNeuron gets go-ahead for phase IIb stroke trial

“The board of the company believes that the share capital reorganisation will result in a capital structure more conducive to attracting new institutional investors based both in the UK and in other overseas jurisdictions,” investors were told.

The proposal will be put to a shareholder vote on January 23.

For more information on the ReNeuron share re-organisation, particularly how fractional shareholdings will be treated, click here.

View full RENE profile View Profile

ReNeuron Group Plc Timeline

Related Articles

Pharmaceuticals
June 28 2018
The AIM-listed pharmaceuticals developer said the contract delays meant that its first-half revenue was expected to be “below management’s expectations”
1530537220_Blood-Test.jpg
July 02 2018
The research and diagnostic company develops cancer-detecting blood tests
1521490126_shutterstock_234586750.jpg
March 19 2018
The group has received key permits to allow cannabis - flowers and oils - to be imported into Australia from Aurora Cannabis Inc

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use